Resumen

BERRIOS-BARCENAS, Enrique A. et al. Mexican position paper for the diagnosis and treatment of cardiac amyloidosis. Arch. Cardiol. Méx. [online]. 2024, vol.94, suppl.3, pp.1-33.  Epub 09-Sep-2025. ISSN 1665-1731.  https://doi.org/10.24875/acm.m24000097.

Amyloidosis is a heterogeneous, hereditary or acquired disease characterized by the abnormal deposition of fibrillar proteins in various tissues. The disease can be either localized or systemic, leading to significant variability in its clinical presentation and often causing diagnostic delays. For this reason, early identification of signs and symptoms is essential to improve prognosis. The first Mexican position paper on cardiac amyloidosis aims to summarize the main features of the disease and its subtypes, identifying warning signs that increase clinical suspicion. Additionally, it provides a diagnostic algorithm incorporating the imaging and laboratory studies available in our country, to streamline decision-making and facilitate a fast, practical, and up-to-date diagnosis based on evidence-based recommendations. Once the diagnosis is confirmed, the various therapeutic challenges of this disease, both pharmacological and non-pharmacological, are discussed, as patients do not respond to conventional heart failure treatments. Therefore, treatment must be individualized for each patient, considering the presence of other comorbidities. Finally, the key prognostic factors are outlined to guide appropriate treatment, including results from genetic counseling.

Palabras llave : Amyloidosis; Cardiac amyloidosis; inmunoglobulin light-chain amyloidosis; Transthyretin; Diagnosis; Prognosis. Treatment.

        · resumen en Español     · texto en Español     · Español ( pdf )